[Clinical application of dienogest: Chinese expert consensus]
article
OA: closed
CC0
AI-generated summary
This expert consensus provides standardized guidance on the clinical application of dienogest for endometriosis and adenomyosis, covering its scope, efficacy, safety, and management of adverse effects.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
地诺孕素是第4代选择性高效孕激素，因其良好的治疗效果及安全性被推荐用于子宫内膜异位症（内异症）及子宫腺肌病的药物治疗。本共识由国内内异症治疗领域的专家共同制定，结合了国内外相关研究和实践经验，对于地诺孕素在内异症治疗中的应用范围、疗效评价、安全性等方面进行了详细的阐述和规范化的指导，对地诺孕素的常见不良反应的临床处理方法以及长期使用的安全性问题给予了以循证证据为基础的专家指导建议。本共识通过推动地诺孕素在内异症治疗中的规范化应用，有望为更多内异症患者带来更好的临床效果和治疗体验。.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-09-27T09:11:36.575535+00:00
- openalex
- last seen: 2026-05-10T10:46:37.739636+00:00
- pubmed
- last seen: 2026-09-26T06:12:51.613776+00:00
License: CC0
· commercial use OK